Show simple item record

dc.contributor.authorWagemaker, Gerard
dc.date.accessioned2020-02-13T10:53:13Z
dc.date.available2020-02-13T10:53:13Z
dc.date.issued2014
dc.identifier.issn1043-0342
dc.identifier.urihttps://doi.org/10.1089/hum.2014.102
dc.identifier.urihttp://hdl.handle.net/11655/22061
dc.description.abstractAfter more than 20 years of development, lentiviral hematopoietic stem cell gene therapy has entered the stage of initial clinical implementation for immune deficiencies and storage disorders. This brief review summarizes the development and applications, focusing on the lysosomal enzyme deficiencies, especially Pompe disease.tr_TR
dc.language.isoentr_TR
dc.publisherMary Ann Liebert, Inctr_TR
dc.relation.isversionof10.1089/hum.2014.102tr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectStem celltr_TR
dc.subjectMetabolic disorderstr_TR
dc.subjectLentiviral hematopoietictr_TR
dc.subject.lcshTıptr_TR
dc.titleLentiviral Hematopoietic Stem Cell Gene Therapy in Inherited Metabolic Disorderstr_TR
dc.typeinfo:eu-repo/semantics/reviewtr_TR
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalHuman Gene Therapytr_TR
dc.contributor.departmentKök Hücretr_TR
dc.identifier.volume25tr_TR
dc.identifier.issue10tr_TR
dc.identifier.startpage862tr_TR
dc.identifier.endpage865tr_TR
dc.indexingWoStr_TR
dc.fundingYoktr_TR


Files in this item

This item appears in the following Collection(s)

Show simple item record